 Xencor, Inc. NASDAQ: XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. Atreca NASDAQ: BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology. 